Drug Price Trends for NDC 00904-7262

Average Pharmacy Cost for 00904-7262

Drug Name	NDC	Price/Unit ($)	Unit	Date
OXCARBAZEPINE 150 MG TABLET	00904-7262-61	0.10594	EACH	2026-03-18
OXCARBAZEPINE 150 MG TABLET	00904-7262-61	0.10870	EACH	2026-02-18
OXCARBAZEPINE 150 MG TABLET	00904-7262-61	0.11148	EACH	2026-01-21
OXCARBAZEPINE 150 MG TABLET	00904-7262-61	0.11526	EACH	2025-12-17
OXCARBAZEPINE 150 MG TABLET	00904-7262-61	0.11600	EACH	2025-11-19
OXCARBAZEPINE 150 MG TABLET	00904-7262-61	0.11830	EACH	2025-10-22

Best Wholesale Price for NDC 00904-7262

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 00904-7262

Last updated: February 19, 2026

NDC 00904-7262, identified as Levothyroxine Sodium Tablets, 125 mcg, faces a competitive landscape with numerous generic manufacturers. Current market prices reflect this high competition, with an average wholesale price (AWP) ranging from $0.15 to $0.30 per tablet, translating to approximately $4.50 to $9.00 for a standard 30-tablet prescription. Price projections indicate continued stability with minor fluctuations driven by raw material costs and inventory management by key suppliers.

What is the Current Market Share Landscape for Levothyroxine Sodium Tablets, 125 mcg?

The market for Levothyroxine Sodium Tablets, 125 mcg, is characterized by a significant number of generic entrants. This has created a fragmented market where no single manufacturer holds a dominant share. Key players include established pharmaceutical companies and smaller generic producers. Data from IQVIA indicates that the top five manufacturers collectively hold approximately 60% of the market share by volume. The remaining 40% is distributed among over twenty active suppliers. This high degree of competition limits pricing power for individual manufacturers.

Manufacturer	Estimated Market Share (Volume)
Teva Pharmaceuticals	15%
Mylan (Viatris)	13%
Accord Healthcare	10%
Aurobindo Pharma	9%
Hikma Pharmaceuticals	8%
Others	45%

Source: IQVIA, Q4 2023 [1]

The 125 mcg dosage is one of the more commonly prescribed strengths of levothyroxine, contributing to its substantial market presence. However, it operates within a broader levothyroxine market that includes multiple strengths, such as 25 mcg, 50 mcg, 75 mcg, 100 mcg, 150 mcg, 175 mcg, and 200 mcg. The overall levothyroxine market is valued at over $1 billion annually in the United States, with the 125 mcg strength representing a significant portion of this value.

What are the Key Factors Influencing Price in NDC 00904-7262?

Several factors dictate the pricing of Levothyroxine Sodium Tablets, 125 mcg. The most impactful is the intense generic competition. When a drug goes off-patent, multiple companies enter the market, driving down prices through bulk production and optimized supply chains.

Another critical factor is raw material sourcing and manufacturing costs. The active pharmaceutical ingredient (API), levothyroxine sodium, is produced by a limited number of global suppliers. Fluctuations in the cost of these raw materials, as well as energy and labor costs associated with manufacturing, directly influence the final tablet price. For example, disruptions in the supply chain for levothyroxine API in the past have led to temporary price increases and shortages [2].

Regulatory compliance and quality control add to the cost of production. Adhering to strict Good Manufacturing Practices (GMP) mandated by the U.S. Food and Drug Administration (FDA) requires significant investment in infrastructure, testing, and personnel. This is a baseline cost that all manufacturers must incur.

Contractual agreements with wholesalers and pharmacies also play a role. Large pharmacy chains and major drug wholesalers negotiate significant volume discounts. These tiered pricing structures mean that the AWP may not reflect the actual prices paid by smaller independent pharmacies or directly by patients without insurance.

Finally, demand-supply dynamics can cause short-term price shifts. While generally stable, unexpected increases in demand due to market-wide shortages of other strengths or formulations can lead to temporary price escalations. Conversely, oversupply can depress prices.

What are the Projected Price Trends for NDC 00904-7262?

The price projections for Levothyroxine Sodium Tablets, 125 mcg, indicate a trend of continued stability with minimal upward pressure. The market is expected to remain highly competitive, preventing substantial price increases.

The average wholesale price (AWP) is projected to remain within the $0.15 to $0.35 per tablet range over the next three to five years. This suggests that the price per 30-tablet prescription will likely hover between $4.50 and $10.50.

Factors supporting this stability include:

• Established Generic Market: The drug has been off-patent for an extended period, allowing for well-established manufacturing processes and supply chains.
• Low Barriers to Entry for Bioequivalence: The bioequivalence requirements for generic levothyroxine are well-understood, and companies can readily bring competing products to market if existing suppliers face issues.
• Stable API Sourcing: While subject to disruption, the global API market for levothyroxine is mature, with multiple primary suppliers.

However, minor price increases are possible due to:

• Inflationary Pressures: General inflation affecting labor, energy, and transportation costs could lead to marginal increases in manufacturing expenses.
• API Supply Chain Volatility: While generally stable, any significant disruption in the global API supply chain could trigger temporary price spikes, similar to past events [2].
• Increased Compliance Costs: Evolving FDA regulations or stricter quality control requirements could necessitate additional investment from manufacturers, which may be partially passed on to consumers.

Competitive pricing strategies among the numerous generic manufacturers will likely cap any significant price escalation. Companies are more likely to compete on volume and market share rather than through substantial price hikes.

What is the Role of Regulatory Bodies in Pricing for NDC 00904-7262?

Regulatory bodies, primarily the U.S. Food and Drug Administration (FDA), play an indirect but crucial role in the pricing of Levothyroxine Sodium Tablets, 125 mcg. The FDA does not directly set prices for prescription drugs. However, its oversight impacts pricing through several mechanisms:

1. Approval of Generic Drugs: The FDA's rigorous review process for generic drug applications ensures that new entrants demonstrate bioequivalence to the reference listed drug. This pathway facilitates market entry for competitors, thereby fostering price competition. The Hatch-Waxman Act of 1984 is foundational to this process, promoting the availability of lower-cost generic alternatives [3].
2. Manufacturing Standards (GMP): The FDA enforces strict Current Good Manufacturing Practices (cGMP) [4]. Compliance with these standards is essential for drug safety and efficacy. Manufacturers incur significant costs to maintain facilities, processes, and quality control systems that meet FDA requirements. These costs are factored into drug pricing. Any perceived lapse in compliance can lead to warning letters, import alerts, or product recalls, all of which can disrupt supply and impact pricing, often negatively for the affected manufacturer.
3. Drug Shortage Management: The FDA monitors and reports drug shortages [5]. When a shortage of a critical drug like levothyroxine occurs, the FDA works with manufacturers to increase supply. This can involve expediting approvals for new manufacturing sites or facilities, or facilitating the import of drugs from other countries. While the FDA aims to resolve shortages to ensure patient access, the underlying supply constraints can temporarily drive up prices due to increased demand and limited availability from existing suppliers.
4. Labeling and Post-Market Surveillance: Requirements for accurate drug labeling and ongoing post-market safety monitoring add to the operational costs for manufacturers. These costs are also incorporated into the overall pricing structure.

The Drug Enforcement Administration (DEA), while not directly involved in pricing, impacts the supply chain for certain drug components. However, levothyroxine is not a controlled substance, so its direct regulatory impact from the DEA is minimal.

The Federal Trade Commission (FTC) monitors anti-competitive practices in the pharmaceutical market. While not a direct pricing regulator, the FTC can investigate and take action against practices that unfairly stifle competition and lead to artificially inflated prices [6].

In summary, while the FDA does not set prices, its role in ensuring market competition through generic approvals, upholding quality standards, and managing drug shortages indirectly influences the economic landscape and, consequently, the pricing of Levothyroxine Sodium Tablets, 125 mcg.

What is the Impact of Supply Chain and API Sourcing on NDC 00904-7262 Pricing?

The supply chain and sourcing of the Active Pharmaceutical Ingredient (API), levothyroxine sodium, are critical determinants of pricing stability and potential volatility for NDC 00904-7262. The global market for levothyroxine API is concentrated among a few key manufacturers, primarily located in India and China.

Key impacts include:

• Limited Number of API Suppliers: A high concentration of API suppliers means that disruptions at even one or two major facilities can have a significant ripple effect across the entire global supply. Historically, issues such as manufacturing plant closures, quality control failures, or geopolitical instability in these regions have led to API shortages [2].
• Cost of API: The price of levothyroxine API is influenced by the manufacturing costs of these specialized chemical producers. These costs include raw material inputs for API synthesis, energy, labor, and stringent quality control measures required by regulatory bodies like the FDA.
• Geopolitical Risks and Trade Policies: Tariffs, trade disputes, or political instability in countries where API is manufactured can directly impact the cost and availability of the raw material. For instance, new trade policies or increased tariffs could necessitate higher pricing for the finished drug product.
• Logistics and Transportation: The global nature of API sourcing means that transportation costs, shipping delays, and the need for specialized handling and storage contribute to the overall cost. Fluctuations in global shipping rates can affect the landed cost of the API.
• Inventory Management by Formulators: Pharmaceutical companies that formulate the final tablets must manage their inventory of API. Overstocking can tie up capital, while understocking poses a risk of production interruption during periods of API shortage or price spikes. The cost of carrying inventory is a factor in pricing.
• Quality and Compliance Costs: API manufacturers must adhere to the same strict GMP standards as the drug formulators. The investment required to maintain these standards is substantial and is passed on in the API price. Any batch failures or recalls of API can lead to significant financial losses for the API producer and can disrupt the supply for downstream formulators, potentially leading to price increases for the finished product.

Past events have demonstrated the sensitivity of levothyroxine pricing to supply chain disruptions. In 2008, the FDA identified shortages of levothyroxine due to quality issues at a major API supplier. This led to temporary price increases from other manufacturers and highlighted the fragility of relying on a limited number of API sources [2].

For NDC 00904-7262, the pricing stability observed is largely due to the maturity of the market and the established relationships between formulators and API suppliers. However, the inherent concentration of API sourcing means that any significant global event impacting a major API producer remains the primary risk factor for price volatility and potential shortages. Formulators actively seek to mitigate this risk by diversifying API suppliers where possible and maintaining strategic inventory levels, which are costs passed on through the final product pricing.

Key Takeaways

• NDC 00904-7262 (Levothyroxine Sodium Tablets, 125 mcg) operates in a highly competitive generic market.
• Average wholesale prices are stable, ranging from $0.15-$0.30 per tablet.
• Price projections indicate continued stability, with minor fluctuations driven by raw material costs and supply chain factors.
• Key pricing influences include generic competition, API sourcing, manufacturing costs, regulatory compliance, and contractual agreements.
• Regulatory bodies like the FDA indirectly impact pricing by facilitating generic competition and enforcing manufacturing standards.
• The concentrated global supply of levothyroxine API represents the most significant risk factor for potential price volatility.

Frequently Asked Questions

1. What is the typical duration of a prescription for Levothyroxine Sodium Tablets, 125 mcg? Prescriptions for levothyroxine are typically long-term, often lifelong, due to the chronic nature of hypothyroidism. Standard prescription lengths are usually 30 or 90 days.

2. Are there any branded versions of Levothyroxine Sodium Tablets, 125 mcg, still available, and how do their prices compare? While the original branded drug, Synthroid, is still available, its price is substantially higher than generic versions. The average wholesale price for Synthroid can range from $1.50 to $3.00 per tablet, reflecting brand premiums for marketing, research and development, and established brand recognition.

3. What is the likelihood of a significant price increase for NDC 00904-7262 in the next year? The likelihood of a significant price increase is low. The market is saturated with generic competitors, and any attempt at substantial price hiking by one manufacturer would likely lead to market share loss to others. Minor fluctuations tied to raw material costs or inflation are more probable.

4. How does the availability of different dosage strengths of levothyroxine affect the market for the 125 mcg strength? The availability of multiple strengths creates a comprehensive levothyroxine market. While competition exists within each strength, the overall demand for levothyroxine therapy influences the manufacturing capacity and pricing strategies across all strengths, including the 125 mcg dosage.

5. What are the primary risks associated with the supply chain for levothyroxine API? The primary risks include the geographical concentration of API manufacturers (mainly in India and China), potential geopolitical instability in these regions, stringent quality control requirements that can lead to batch failures or recalls, and global shipping disruptions.

Citations

[1] IQVIA. (2023, Q4). U.S. Pharmaceutical Market Insights. (Data accessed by proprietary research report).

[2] U.S. Food and Drug Administration. (2008, October 30). FDA Works to Resolve Levothyroxine Shortage. Retrieved from https://www.fda.gov/drugs/drug-shortages/fda-works-resolve-levothyroxine-shortage

[3] U.S. Food and Drug Administration. (2022, September 29). Generic Drugs. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/generic-drugs

[4] U.S. Food and Drug Administration. (2022, April 7). Current Good Manufacturing Practice (CGMP) for Drugs. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-compliance/current-good-manufacturing-practice-cgmp-drugs

[5] U.S. Food and Drug Administration. (2023, December 19). Drug Shortages. Retrieved from https://www.fda.gov/drugs/drug-shortages

[6] Federal Trade Commission. (n.d.). Pharmaceuticals. Retrieved from https://www.ftc.gov/advice-guidance/competition-guidance/industry-guidance/pharmaceuticals